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Abstract
Background: Liposarcoma is the single most common soft tissue sarcoma in the retroperitoneum.
Materials and methods: A retrospective review of patients with primary retroperitoneal liposarcoma treated
between June 1990 and June 2005 were conducted to evaluate the clinical results of resection for retroperitoneal
liposarcomas (RPLS) and the prognostic factors for disease recurrence and patient survival in an Asian population.
Results: Twenty-one patients operated on for curative intent (12 Males, 9 Females; mean age: 52.4 years) were
evaluated. Of these, 13 presented with tumors that were well differentiated (61.9%), 4 (19.0%) with myxoid/round
cell, 3 (14.3%) with dedifferentiated and 1(4.8%) with pleomorphic morphology. The median tumor burden was 36
cm (9-83). Median follow-up time was 62 months. There was no peri-operative mortality and morbidity occurred in
6(28.6%) patients. Surgical margins were involved in 10(47.6%) patients. Resection of contiguous organs was
required in 15(71.4%) to achieve gross surgical margins. Eleven out of the 21(52%) of the patients had recurrence
of the tumor. Median disease-free survival was 19 months and the overall 3- and 5-year survival rate was 87% and
49% respectively.
Conclusion: An aggressive surgical approach in both primary and recurrent RPLS in our institution is associated
with 3- and 5-year survival rate of 87% and 49% respectively. Contiguous organ resection is often required to
achieve local control.
Introduction
Soft tissue sarcomas are rare and account for less than 1%
of all newly diagnosed malignancies. One third of malig-
nant tumors that arise in the retroperitoneum are sarco-
mas. Liposarcoma is the single most common soft tissue
sarcoma and the most common retroperitoneal sarcoma.
It accounts for at least 20% of all sarcomas in adults and
up to 41% of all retroperitoneal sarcomas [1,2]. Retroperi-
toneal liposarcomas (RPLS) grow slowly and silently. Its
prognosis is poor compared to the other histological sub-
types of retroperitoneal sarcomas [3,4]. Only complete
excision provides a hope of a cure, this is often difficult,
especially in well differentiated subtypes because the mar-
gins are not grossly apparent thus often necessitating con-
tiguous organ resection. Classification of liposarcoma into
subtypes based on morphologic features and cytogenetic
aberrations is now widely accepted. The 4 subtypes
includes Well-differentiated, De-differentiated, Myxoid/
Round cell and Pleomorphic [5].
Previous studies have shown that high histological
grade and incomplete gross resection are the most
important negative prognostic factors in patients with ret-
roperitoneal sarcoma. Complete surgical excision is the
mainstay of treatment. Some previous reports suggested
that there is no survival benefit of partial resection as
compared to biopsy alone without resection [2,6-8].
There is however no universal agreement and at least
one series reported that in selected patients with retro-
peritoneal liposarcomas, partial resection can prolong
survival and provide palliation [1]. medical therapies have
shown some efficacy in the management of RPLS,
although most consensus is that total surgical extirpation
provides the patient best chance for cure [9-11].
The aim of this study is to review our experience in
the management of RPLS in an Asian population and to
identify any associated prognostic factors.
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Between July 1990 and June 2005, 91 consecutive patients
who underwent surgical resection for a retroperitoneal
tumor or mass at our institution were identified from a
prospectively maintained database. Twenty-one patients
with primary pathologically proven retroperitoneal lipo-
sarcoma were treated between this period. Their clinical
data and operative notes, radiological reports and patho-
logical reports were reviewed retrospectively. Histology at
primary presentation was reviewed and classified into
4 distinct subtypes (Well-differentiated, De-differentiated,
Myxoid/Round cell and Pleomorphic) according to
the World Health Organization (WHO) classification
and graded 1, 2 or 3 according to the French Federation
of Cancer Centers Sarcoma Group grading systems
[3,12,13].
Morbidity and mortality analyses were conducted by
reviewing patient charts and clinical records. Operative
morbidity and mortality was defined as any significant
complications or death within 30 days of surgery follow-
ing surgery. Significant complications included wound
infection and dehiscence, reactionary hemorrhage neces-
sitating repeat surgery, post-operative pneumonia, cul-
ture-proven septicemia, radiological identification of an
intra-abdominal abscess, enterocutaneous fistula or con-
firmed deep vein thrombosis and/or pulmonary embo-
lism. Margins were defined as microscopically clear if
there was not tumor within 1 mm or more of the edge
of the inked surgical margin. The tumor burden was
determined by the sum of the 3 maximum tumor dia-
meters and tumor size was defined as the maximum
tumor diameter.
Patients were followed up at the specialist outpatient
clinics at approximately 3-month intervals during the
first year and 6-month intervals thereafter. Information
obtained during follow-up included status of disease
(alive with or without clinical evidence of disease, dead
of disease or treatment, dead of other causes without
evidence of disease). CT or MRI was performed at
6-month interval or earlier if there was clinical suspicion
of recurrence or at the surgeon’s discretion. Recurrence
was defined as the time of initial surgery to confirma-
tion of clinical recurrence by imaging e.g. CT or MRI.
In this study, the Kaplan-Meier estimate of the survi-
val curve was used to summarize the data. Univariate
analysis and comparison was performed for each factor
of interest using Tarone-ware test. Tarone Ware test is
a modification of the log rank test for comparing two
survival curves with censored data and it is chosen as its
key benefit is that it is designed to provide a valid statis-
tical test, even with a large fraction of censored data.
P < 0.05 was considered statistically significant [14].
Results
Clinico-pathological characteristics
The patient’s demographic, surgical and pathological
data are summarized in Table 1. Twenty-one patients
with primary retroperitoneal liposarcoma operated on
with curative intent (12 Males, 9 Females; mean age:
52.4 years, range: 29-71) were evaluated. The median
age for patients at presentation was 53.13 years; most of
them were above 40 years of age, except one who was
28 years old. The median duration of hospitalization
w a s1 0d a y s( r a n g e :7t o2 7d a y s ) .T h em o s tc o m m o n
symptom at presentation was abdominal discomfort and
distension (24%) and 2 patients presented with symp-
toms as a result of mass effect namely bilateral lower
limb edema and urinary frequency. An abdominal mass
was palpable in the majority, 16 of the patients at pre-
sentation (76%). Of these, 13 presented with tumors
that were well differentiated (61.9%), 4 (19.0%) with
myxoid/round cell, 3 (14.3%) with dedifferentiated and
Table 1 Clinico-pathologic and Treatment Characteristics
in Patients with Primary Liposarcoma of the
Retroperitoneum
Variables Mean/median/n
(percentage %)
Age
Mean (std) 53.36 (11.47)
Median (range) 53.13 (28.56, 71.89)
Gender (n, %)
Male 12 (57.1)
Female 9 (42.9)
Duration of Hospitalization
Median (range) 10 (7, 27)
Grade (n, %)
Grade 1 11 (52.4)
Grade 2 3 (14.3)
Grade 3 7 (33.3)
Histology (n, %)
Well differentiated 13 (61.9)
Myxoid/Round cell 4 (19.0)
DeDifferentiated 3 (14.3)
Pleomorphic 1 (4.8)
Tumor size (n, %)
< = 20 cm 12 (57.1)
> 20 cm 9 (42.9)
Margins (n, %)
Positive 10 (47.6)
Negative 11 (52.4)
Resection of contiguous organs (n, %)
Yes 15 (71.4)
No 6 (28.6)
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Page 2 of 61(4.8%) with pleomorphic morphology. Eleven patients’
(52.4%) tumors were classified as grade 1, 3 were grade
2(14.3%) tumors and the remaining 7 were grade
3(33.3%) tumors. The tumor burden was determined by
the sum of the 3 maximum tumor diameters and tumor
size was defined as the maximum tumor diameter. The
median tumor burden was 36 cm (Range 9-83 cm).
Twelve patients had tumors maximum diameter smaller
than 20 cm whereas 9 patients has tumor larger then 20
cm. The largest tumor diameter was 43 cm. Median fol-
low-up time was 62 months (Range 0.05 to 10.39 years).
There was no post-operative mortality, morbidity
occurred in 6(28.6%) patients. Surgical margins were
involved in 10(47.6%) patients. Resection of contiguous
organs was required in 15(71.4%) to achieve gross surgi-
cal margins.(Table 1) Eleven out of the 21(52%) of the
patients had tumor recurrence.
Disease free and overall survival analysis
In this series, median disease-free interval and median
overall survival was 19 months and 52 months respec-
tively. The overall 3- and 5-year survival rate was 87%
and 49% respectively. (Figure 1)
The univariate analysis of gender, age at presentation,
tumor size, positive surgical margins, tumor differentia-
tion, tumor grade and presence of contiguous organ
resection were analyzed with regards to disease-free sur-
vival and overall 3- and 5-year survival rate. This was
summarized in Table 2.
In our series, females have a 3- and 5-year overall sur-
vival (OS) at 83.3% and 27.8%. respectively; the males
patients have a 3-year OS of 90% and 5-year OS of
67.5%, this was not statistically significant. In comparing
the age of presentation, patients older than 50 years of
age have a 90% and a 45% 3- and 5-year OS respec-
tively, as compared to 83.3% and 55.6% for 3- and
5 year-OS in patients who are younger than 50 years of
age. Three year DFS is at 33.3% for patients who pre-
sented at 50 years of age and 61% for those 50 years or
older. This is not statistically significant.
Patients with tumors that are 20 cm or larger have a
trend to do worse but no significance is detected. The
3-year; 5-year OS and 3-year DFS for patients whose
tumors that are larger than 20 cm at presentation are
80.8%, 40.4% and 28.1% as compared to 100%, 66% and
75% respectively (Patients with largest tumor diameter
smaller then 20 cm)(P = 0.379). Patients with positive
margins also seem to have a worse trend in terms of
overall survival and recurrence. Patients with positive
microscopic margins had a 3-year OS, 5-year OS and 3-
year DFS rate of 88.9%, 44.4% and 31.7% as compared
to 87.5%, 58.3% and 62.5% respectively, in patients with
negative microscopic margins.(P = 0.757). Patients with
well differentiated tumors had a trend for a better 3-, 5-
year OS than those with other subtypes (90.9% and
83.3% vs. 54.5% and 44.4%), however, the well differen-
tiated tumors tend to recur earlier than the other sub-
types in our series of patients (DFS, 32.8% vs. 60%),
although there is no significance detected. This is con-
sistent with the nature of well differentiated liposarco-
mas which is known to have more loco-regional
recurrences than other subtypes.
We did not detect any statistical difference in OS and
DFS between the different tumor grades Patients who
required contiguous organ resection to achieve gross sur-
gical resection also do not do worse in our study. The
3-year OS, 5-year OS and 3-year DFS for patients who
required contiguous organ resection were 100%, 40% and
40% as compared to 60%, 60% and 51.4%(patients with-
out the need for contiguous organ resection, respectively.
(P = 0.248) (Table 2) In the group of patients with con-
tiguous organ resection (n = 15), the kidney was the most
common organ resected (n = 5), followed by the colon
(n = 4), the spleen(n = 2) and the pancreas (n = 2). Four
patients required 2 or more organs resected.
There was no significance prognostic factors detected
in our series, this is probably due to small sample size
with the result of a Type II error.
Discussion
Liposarcomas is the most common mesenchymal tumor
of the retroperitoneal space but RPLS continues to pose
a challenge with regards to diagnosis, prediction of clini-
cal behavior, and treatment of disease recurrence within
the intra-abdominal and retroperitoneal space. Retroper-
itoneal liposarcomas tend to be of low to intermediate
grade, while other sarcomas of other histologic types e.g.
leiomyosarcomas in this location tend to be high grade
[4,15,16]. Sarcomas are believed to arise de novo, spread-
ing by direct, local extension or hematogenous routes,
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Page 3 of 6metastases at the time of initial presentation are uncom-
mon. However, if metastatic, the lungs are the most
common site of initial metastases.
The two largest series to date on RPLS were published
in the Western population by Neuhaus et al. and Singer
et al., however, there is little data in the current litera-
ture describing RPLS in the Asian population [4,16].
Histological grade was consistently reported to be the
most important factor affecting survival rates for
patients with liposarcomas [17]. In our series by com-
paring tumors that are grade 1 against grade 2 and
3 tumors, there was no statistical significance detected
probably due to the limited sample size. The median
tumor burden of 36 cm for our patients also appears to
be larger than that reported in western literature [4].
There are two widely accepted grading systems interna-
tionally for soft tissue sarcomas, the National Cancer
Institute (NCI) and the French Federation of Cancer
Centres (FNCLCC) grading system. Both systems have
proven to have prognostic value and share several fea-
tures e.g. the emphasis on the histological type and the
evaluation of the amount of necrosis. Neither of the
systems is endorsed solely by the Association of Directors
of Anatomic and Surgical Pathology or the WHO as yet
[12,18]. To further aid in risk stratification and prognos-
tication, nomograms are becoming a popular tool; Mem-
orial Sloan-Kettering has designed and validated their
nomogram for 12-year sarcoma-specific mortality utiliz-
ing seven histological types as considerations to calculate
the probability of a patient reaching a designated clinical
end-point [19,20]. Despite these problems, grading of sar-
comas has been an important progress pathologists have
contributed to the treatment of sarcomas. Grading iden-
tifies patients at highest risk of distant metastasis and
aggressive tumor behavior, thus helps and guides oncolo-
gists in the management of these patients.
From the literature, the overall 5-year survival for well-
differentiated subtypes is 90%, while 5-year survival for
pleomorphic subtypes is only 30-50%. De-differentiated
and myxoid/round cell subtypes have intermediate 5-year
survival rates of 75% and 60-90%, respectively. Well-
differentiated liposarcomas may recur locally, but meta-
static potential is low. Pleomorphic liposarcomas have
high metastatic potential, accounting for the decreased
rate of survival [4]. It been reported recently that
well differentiated liposarcomas and de-differentiated
liposarcomas have different biological behaviors, in
de-differentiated tumors, they tend to present as a recur-
rence more often, require multi-organ resection more
frequently and has a shorter disease free interval when
compared to well differentiated subtypes [21]. In our ser-
ies, out of the 11 patients with recurrence, all of them
had loco-regional recurrence and the majority of them
have well differentiated subtypes (n = 7, 64%) with only
one patient with concurrent liver metastases. Our aggres-
sive surgical policy of achieving gross negative margins
including contiguous organ resection if necessary have
resulted in comparable survival rates despite the median
tumor burden larger compared to the western literature.
In the literature, factors with negative prognostic value
regarding survival include de-differentiation subtype,
grade 2-3, stage II-III, size >20 cm, and involved surgical
m a r g i n s[ 4 ] .I no u rs e r i e s ,s o m eo ft h e s ef a c t o r sa l s o
showed a negative prognostic trend although it did not
reach any statistical significance. The retroperitoneal
location is a negative prognostic factor and a significant
risk factor when considering local recurrence of disease.
Distant metastasis is more common with de-differentia-
tion, grade II-III, and deep seated location [17]. Distant
metastasis also relates to tumor size. In a review of
460 patients with liposarcoma of which 35% are RPLS
(n = 159) who had achieved local control of their dis-
ease, recurrence and incidence of metastatic disease at
5 years was noted to increase significantly with
increased tumor size at initial evaluation [22]. The RPLS
is of special interest as the retroperitoneum is the
Table 2 Risk factors for overall survival and disease free
survival after operation (p-values of the Tarone-ware test
are presented)
Risk factors 3-year
survival rate
5-year
survival rate
p-value
Gender 0.544
Male 90% 67.5%
Female 83.3% 27.8%
Age (>50 years) 0.843
< = 50 83.3% 55.6%
>50 90% 45%
Tumor size (> 20 cm) 0.379
< = 20 100% 66.7%
> 20 80.8% 40.4%
Margins 0.757
Negative 87.5% 58.3%
Positive 88.9% 44.4%
Degree of Differentiation 0.997
Well differentiated 90.9% 83.3%
Not well differentiated 54.5% 41.7%
Grade 0.718
1 88.9% 44.4%
2 & 3 85.7% 57.1%
Organ resection 0.248
Yes 100% 40%
No 60% 60%
Tarone-ware test (which can be applied in case of non proportional hazard)
was used to compare the overall survival rates for each covariates of interest.
Although 3-year and 5-year survival rates were both higher for male patients,
patients with tumor size >20 cm and well differentiated, no significant
difference could be detected using Tarone-ware test, this might be due to the
small sample size.
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36% of liposarcomas occurring at this site. The tumor is
often deep-seated and large at the time of diagnosis as
the retroperitoneum space provides a large potential
volume allowing sizeable growth prior to development
of signs and symptoms [4,17]. In our series, consistent
with the current literature, we found that the presence
of contiguous organ resection and tumor size of greater
than 20 cm was negatively associated with prognosis,
although due to a small sample size, there was no statis-
tical significance detected. The mainstay of treatment is
complete surgical resection. Complete resection was
often challenging as the tumor may be difficult to distin-
guish from normal retroperitoneal fat. Furthermore,
adjacent organs involved by the tumor may also need to
be resected [4]. Failure to achieve macroscopic clearance
was often due to the size of the tumor and the need for
extensive visceral resection. Retroperitoneal liposarco-
mas is often large at presentation and can grow to enor-
mous size, weighing over 100 pounds and measuring 50
cm in maximum diameter [23]. The largest tumor dia-
meter in our series was 43 cm, with almost half of the
tumors measuring more than 20 cm (42.9%). Studies
had shown that complete resection may increase overall
5-year survival to 58% from 16.7% [17]. These tumors
usually arise from the perinephric fat and as a result,
kidney involvement was not unexpected, they often dis-
placed the kidney peripherally or caused the kidney to
be rotated away and in advanced cases the tumor may
encase the kidney or cause pelvi-ureteric obstruction.
Kidney was the most common organ resected followed
by the colon and this was shown in our series as well.
In a palliative setting, the colon was the organ most
commonly resected followed by the kidney [16]. Nota-
bly, our series has a high rate of contiguous organ resec-
tion as compared to some earlier larger western series
[4] (76% vs. 26%), this is mostly likely attributed by the
larger tumor burden of our patients but our percentage
of achieving negative microscopic margins is comparable
to centres that advocate extensive resections [24,25]. We
postulate that this is in part due to the later presenta-
tion of our Asian patients to tertiary healthcare [26,27].
This delay in presentation may be contributed by the
cultural preference of our patients to seek traditional
medical care over western medicine and the general
reluctance of patients to obtain early medical attention
for their symptoms, tending to ignore even significant
symptoms till the disease is incapacitating or when
family members coax and brings the patient to see a
doctor The level of general medical knowledge is also
poorer in the older generation in many Asian societies
as compared to their Western counterparts. However in
the recent years, as we understand that positive margins
were associated with decreased survival, extensive or
wide resection e.g. compartmental resections have been
shown and advocated, to be performed especially in
high volume tertiary centres, to achieve better outcomes
[24,25].
There is no strong evidence that chemotherapy or
radiotherapy is curative [28,29]. There is no prospective
randomized controlled trial confirming the potential
benefit of radiotherapy that emerges from retrospective
studies [11,30]. Given the large size and truncal location
of retroperitoneal liposarcomas, adjuvant radiation is
often not an option secondary to substantial morbidity
associated with the required radiation doses and fields.
Similarly, in well-differentiated low grade tumors, adju-
vant chemotherapy yields little benefit. In high-grade
disease, administration of adriamycin and ifosfamide
may yield partial responses in up to 50% of patients
with increased overall survival; however, complete
responses are seen in less than 10% of patients [11]. To
date, there are few prospective clinical trials analyzing
chemo-radiotherapy regimes for retroperitoneal sarco-
mas, there is none specific and solely for retroperitoneal
liposarcoma histological subtype [11,30]. Retroperitoneal
recurrences are often difficult to control, with death
most often occurring from local effects of the tumor
burden [17]. Despite an aggressive surgical approach, in
our series we only achieve 5 year OS of 49%, this is
probably in part attributed to the poor efficacy of
neoadjuvant and adjuvant therapies. As such, the biology
and molecular alteration of this disease need to be
further characterized with more basic and translational
research to explore new, innovative targeted therapeutic
agents that target specific translocation or amplification
products, this approach forward may offer promise for
this rare and lethal disease [31].
As RPLS is a rare entity, a multi-institution prospec-
tive database will serve well to understand this disease
more comprehensively. The limitations of our study is
that the review is retrospective in nature and thus prone
to bias, due to the limited sample size, there will be a
element of type II error, resulting in a difficulty of
achieving firm conclusion and statistical significance
with regards to the prognostic factors analysis.
Conclusion
The experience in our institution represents the surgical
experience and behavior of RPLS in an Asian Population
a n dw eh a v ed e m o n s t r a t e dt h a tt h eb e h a v i o ro fR P L S
and most of the results seemed consistent with the cur-
rent western literature although our patients’ tumor bur-
den appears to be slightly larger than that reported in
western literature, necessitating a larger percentage of
them undergoing contiguous organ resection to achieve
gross clear margins. We believe that complete surgical
resection is the most important component of treatment
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achieve gross surgical margins, as it improves survival.
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